Discovery Proteomics Services
Get the Resource
Download NowProteins and their proteoforms are the active mediators of biology. Directly quantifying them provides a more accurate readout of dynamic disease processes and drug effects. Sapient’s discovery proteomics approaches deliver high-specificity, reproducible measures across thousands of proteins simultaneously to maximize discovery potential and confidence in findings.
We utilize next-generation mass spectrometry to directly measure proteins with peptide-level readouts for precise identification, and to provide the throughput to make these measurements across hundreds of samples at a time for statistically-powered discovery.
Why mass spectrometry for discovery proteomics?
Mass spectrometry-based discovery proteomics delivers direct protein measurements with peptide-level sequencing for precise protein identifications. This negates the need for antibodies and the risk of non-specific binding that can limit affinity-based proteomics techniques, and provides complementary insights to validate and extend discoveries made via genomics, RNA sequencing, and with antibody-based proteomic workflows.
Direct measurement also means that mass spectrometry workflows can readily detect splice, truncation, indel, missense, and other non-canonical variants as well as post-translational modifications (PTMs) including phospho-proteins and glyco-proteins.
Additionally, mass spectrometry is applicable across species and in nearly every sample type, supporting efficient translation of findings.
What makes Sapient's discovery proteomics workflows unique?
Sapient’s mass spectrometry-based discovery proteomics methods combine label-free, DIA workflows with advanced protein extraction and enrichment techniques to maximize proteome coverage across diverse sample matrices. This includes specialized
‘capture-and-hold’ nanoparticle chemistry in plasma to capture the low-abundance proteome. Single fraction-single injection processing yields exceptional reproducibility for:
- FFPE Proteomics – enabling deep measure of 10,000+ protein groups, including phospho- and glyco-proteins, in archived samples
- Tumor Proteomics – enabling deep measure of 12,000+ protein groups, including >1,000 known and emerging drug targets, in fresh-frozen tumor and tissue samples
- Plasma Proteomics – enabling measure of 5,400+ protein groups, including >1,000 known and emerging drug targets
- CSF Proteomics – for discovery proteomics measures across 3,600+ protein groups, including known and emerging drug targets for neurodegenerative diseases
- Saliva Proteomics – enabling measure of 6,000+ protein groups via non-invasive sampling, including >800 known and emerging drug targets
What’s more, as the only multi-omics partner with a population-scale molecular-clinical database – our DynamiQ™ Insights Engine – we can both analyze your samples and validate the findings in independent real-world cohorts.
Download the fact sheet to learn how Sapient’s discovery proteomics approaches can help you elucidate functional biology, novel targets, and the influence of protein variants, supporting:
- Target Identification & Prioritization: to enable rapid discovery and validation of tractable, disease-modifying targets (proteins and PTMs).
- Biomarker Discovery & Validation: providing a much more accurate and actionable view of signaling events, cellular interactions, and mechanistic drivers.
- Mechanistic Insight & MoA Studies: with protein- and pathway-level insights into the dynamic functional events that drive disease processes and therapeutic response.
- Translation to Targeted Assays: we can rapidly move biomarkers and targets identified through our discovery screenings – and validated as human-relevant in DynamiQ – to quantitative targeted assays with analytical validation based on appropriate context of use (COU) statements.